» Articles » PMID: 16172858

Lrrk2 Pathogenic Substitutions in Parkinson's Disease

Overview
Journal Neurogenetics
Specialty Neurology
Date 2005 Sep 21
PMID 16172858
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Leucine-rich repeat kinase 2 (LRRK2) mutations have been implicated in autosomal dominant parkinsonism, consistent with typical levodopa-responsive Parkinson's disease. The gene maps to chromosome 12q12 and encodes a large, multifunctional protein. To identify novel LRRK2 mutations, we have sequenced 100 affected probands with family history of parkinsonism. Semiquantitative analysis was also performed in all probands to identify LRRK2 genomic multiplication or deletion. In these kindreds, referred from movement disorder clinics in many parts of Europe, Asia, and North America, parkinsonism segregates as an autosomal dominant trait. All 51 exons of the LRRK2 gene were analyzed and the frequency of all novel sequence variants was assessed within controls. The segregation of mutations with disease has been examined in larger, multiplex families. Our study identified 26 coding variants, including 15 nonsynonymous amino acid substitutions of which three affect the same codon (R1441C, R1441G, and R1441H). Seven of these coding changes seem to be pathogenic, as they segregate with disease and were not identified within controls. No multiplications or deletions were identified.

Citing Articles

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival.

Kang J, Huang G, Ma L, Tong Y, Shahapal A, Chen P Elife. 2024; 12.

PMID: 38856715 PMC: 11164531. DOI: 10.7554/eLife.92673.


A Next-Generation Sequencing Study in a Cohort of Sicilian Patients with Parkinson's Disease.

Salemi M, Lanza G, Salluzzo M, Schillaci F, Di Blasi F, Cordella A Biomedicines. 2023; 11(12).

PMID: 38137339 PMC: 10740523. DOI: 10.3390/biomedicines11123118.


An Update on the Interplay between LRRK2, Rab GTPases and Parkinson's Disease.

Komori T, Kuwahara T Biomolecules. 2023; 13(11).

PMID: 38002327 PMC: 10669493. DOI: 10.3390/biom13111645.


A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component, SKP1A.

Fishman-Jacob T, Youdim M J Neural Transm (Vienna). 2023; 131(6):675-707.

PMID: 37644186 PMC: 11192832. DOI: 10.1007/s00702-023-02687-6.


Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.

Ito G, Utsunomiya-Tate N Biomolecules. 2023; 13(5).

PMID: 37238714 PMC: 10216118. DOI: 10.3390/biom13050845.


References
1.
Tanner C . Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol. 2002; 91:133-42. View

2.
Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

3.
Fahn S . Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003; 991:1-14. DOI: 10.1111/j.1749-6632.2003.tb07458.x. View

4.
Gilks W, Abou-Sleiman P, Gandhi S, Jain S, Singleton A, Lees A . A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005; 365(9457):415-6. DOI: 10.1016/S0140-6736(05)17830-1. View

5.
Paisan-Ruiz C, Saenz A, de Munain A, Marti I, Martinez Gil A, Marti-Masso J . Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann Neurol. 2005; 57(3):365-72. DOI: 10.1002/ana.20391. View